CNTX — Context Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $1.74m
- $123.04m
Annual income statement for Context Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.57 | 10.4 | 15.4 | 25.1 | 29.9 |
| Operating Profit | -2.57 | -10.4 | -15.4 | -25.1 | -29.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 6.64 | -10.5 | -14.8 | -24 | -26.7 |
| Net Income After Taxes | 6.64 | -10.5 | -14.8 | -24 | -26.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 6.64 | -10.5 | -14.8 | -24 | -26.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 6.64 | -10.5 | -14.8 | -24 | -26.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.606 | -0.661 | -0.929 | -1.5 | -0.458 |
| Dividends per Share |